Promising drug compound for chronic itch identified

Tuesday, September 29, 2015


New York: Researchers have identified a new class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.

Laura Bohn

Laura Bohn

The findings could lead to new treatment for “chronic intractable itch,” a condition where itchy sensation does not easily go away, and which is closely associated with dialysis and renal failure.

The compound that the researchers tested was effective in stopping irritant-induced itch, without causing sedation, in mouse models of the condition.

“Our lab has been working on compounds that preserve the good properties of opioids and eliminate many of the side effects,” said Laura Bohn, professor at The Scripps Research Institute (TSRI), Florida in the US.

“The new paper describes how we have refined an aspect of signalling underlying how the drugs work at the receptor so they still suppress itch and do not induce sedation,” Bohn noted.

The study used a compound called isoquinolinone 2.1 to target a receptor, which is widely expressed in the central nervous system and serves to moderate pain perception and stress responses.

The study was published in the journal Neuropharmacology.


Categories: Dermatology, Pharmacology, RESEARCH

Tags: , , ,

  More from Dermatology

Study examines global burden of skin disease

Promising drug compound for chronic itch identified

Transplant recipients more likely to develop aggressive melanoma

New combination treatment effective against melanoma skin metastases

Researchers beat untreatable eczema with arthritis drug

Ultrasound accelerates skin healing – especially for diabetics and the elderly

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> in your comment.